Company Update (NASDAQ: KBIO): KaloBios Announces Retirement of David W. Pritchard, President and Chief Executive Officer


KaloBios Pharmaceuticals, Inc. (Nasdaq:KBIO) today announced that David W. Pritchard, president and chief executive officer, has decided to retire, effective immediately, and has also resigned his position as a member of the company’s Board of Directors. The company has named Herb C. Cross, chief financial officer, as interim CEO pending a search for a new chief executive officer… Read more

Shares of KaloBios Pharmaceuticals Inc opened today at $0.524 . KBIO has a 1-year high of $5.61 and a 1-year low of $0.47. The stock’s 50-day moving average is $1.76 and it’s 200-day moving average is $1.77.

KaloBios Pharmaceuticals is a biopharmaceutical company engaged in the development of monoclonal antibody therapeutics for diseases that burdens the society and to patients and their families.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts